Fig. 3: Drug concentrations in blood and tissues.

a Median (range) concentrations of CAB and RPV in plasma during treatment. CAB concentrations were measured every week. RPV concentrations were measured 2–4 weeks after dosing. Each data point denotes the median CAB or RPV levels seen in the 4 treated animals in a given week (42 weeks for CAB and 13 weeks for RPV). b Median (range) concentrations of CAB in plasma in the 4 treated macaques during treatment (months 0–12) and after treatment cessation at month 12. The horizontal red line denotes the mean plasma levels seen in humans receiving 400 mg of CAB LA every 4 weeks for 48 weeks. c Median (range) concentrations of RPV in plasma in the 4 treated macaques during treatment (months 0–12) and after treatment cessation at month 12. The horizontal red line denotes the mean plasma levels seen in humans receiving 600 mg of RPV LA every 4 weeks for 48 weeks. The shaded blue area in panels b and c denotes the period of treatment. The dotted black lines denote the protein-adjusted IC₉₀ values (PA-IC₉₀) for CAB (166 ng/ml) and RPV (12 ng/ml). d Median (range) concentrations of TFV-DP in PBMCs measured 24 h post-dosing during the entire study and divided by periods of full adherence to oral FTC/TAF (moths 0–3.5) and periods of suboptimal adherence (months 3.5–6). e Median (range) concentrations of FTC-TP 24 post-dosing were also divided by periods of full adherence and suboptimal adherence. Each data point in panels d and e denotes the median TFV-DP or FTC-TP levels seen in the 4 treated macaques in a given week. f Ratios between dATP or dCTP and intracellular TFV-DP or FTC-TP in PBMCs, LNMCs, and tissues. Horizontal lines denote medians, and the error bars are ranges. Each LNMC data point denotes ratios obtained in 1–3 biopsies per animal. Each PBMC data point denotes ratios obtained in a given week during the period of full adherence to FTC/TAF. Each rectal data point denotes ratios obtained in 2-3 biopsies per animal. Source data are provided as a Source Data file.